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ABSTRACT
Background: Insulin-like growth factor I (IGF-I) is the most
important hormonal promoter of linear growth in infants and young
children.
Objectives: The objectives of this study were to compare plasma
IGF-I concentration in a low- compared with a high-income country
and characterize biological pathways leading to reduced IGF-I
concentration in children in a low-income setting.
Methods: We analyzed plasma IGF-I concentration from 716
Malawian and 80 Finnish children at 6–36 mo of age. In the
Malawian children, we studied the association between IGF-I
concentration and their environmental exposures; nutritional status;
systemic and intestinal inflammation; malaria parasitemia and
viral, bacterial, and parasitic enteric infections; as well as growth
at 18 mo of age. We then conducted a pathway analysis to
identify direct and indirect associations between these predictors and
IGF-I concentration.
Results: The mean IGF-I concentrations were similar in Malawi and
Finland among 6-mo-old infants. At age 18 mo, the mean ± SD
concentration was almost double among the Finns compared with
the Malawians [24.2 ± 11.3 compared with 12.5 ± 7.7 ng/mL,
age- and sex-adjusted difference in mean (95% CI): 11.8 (9.9, 13.7)
ng/mL; P < 0.01]. Among 18-mo-old Malawians, plasma IGF-I
concentration was inversely associated with systemic inflammation,
malaria parasitemia, and intestinal Shigella, Campylobacter, and
enterovirus infection and positively associated with the children’s
weight-for-length z score (WLZ), female sex, maternal height,
mother’s education, and dry season. Seasonally, mean plasma
IGF-I concentration was highest in June and July and lowest
in December and January, coinciding with changes in children’s
length gain and preceded by ∼2 mo by the changes in their
WLZ.
Conclusions: The mean plasma IGF-I concentrations are similar
in Malawi and Finland among 6-mo-old infants. Thereafter, mean
concentrations rise markedly in Finland but not in Malawi. Systemic
inflammation and clinically nonapparent infections are strongly as-
sociated with lower plasma IGF-I concentrations in Malawi through
direct and indirect pathways. Am J Clin Nutr 2021;113:380–390.
Keywords: childhood growth faltering, stunting, infection, hor-
monal regulation, pathway analysis, systemic inflammation
Introduction
Stunting—that is, having a low length or height for age—
is estimated to affect 149 million (21.9%) children <5 y of
age worldwide (1). The condition is associated with increased
mortality and morbidity, poor cognitive development, low
educational attainment, reduced lifetime earnings, and increased
risk of chronic diseases in adulthood (2, 3). Because of its high
prevalence and the associated deleterious outcomes, stunting
among children is now considered a major health threat and its
reduction has become a global development priority (4, 5).
Although the global prevalence of stunting has decreased in
recent years, the changes are modest and insufficient to meet
the global target to reduce by 40% the number of stunted
children <5 y of age by 2025 (1, 6). A major impediment
for faster progress may be inadequate understanding of the
exact biological processes that lead to stunting. According to
a widely accepted causation framework, growth restriction is
related to undernutrition, frequent illnesses, and other adverse
environmental exposures (e.g., poor water source and sanitation)
(7). Currently, however, there is little information on the relative
importance of these factors and the biological pathways by which
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they restrict elongation of long bones, which is a hormonally
regulated process that results in linear growth in children (8).
In infants and young children, the most important hormonal
promoter of linear growth is insulin-like growth factor I (IGF-I),
which is produced in liver and other tissues upon stimulation by
growth hormone and thyroid hormone (8). Most IGF-I is secreted
into the circulation, and it exerts its function by binding to specific
receptors in the cells of epiphyseal growth plates and other
peripheral tissues. Its synthesis is reduced by malnutrition (9) and
systemic inflammation (10), and its plasma concentration shows
little diurnal variation but responds rapidly to external exposures
such as acute illness (11). Because of this responsiveness, short-
term triggers of growth restriction may be better identified by
measuring plasma IGF-I concentration than actual increment in
length or height, which is typically measured over a minimum
period of 3 mo.
In this study, we aimed to characterize biological pathways
associated with plasma IGF-I concentration in children in low-
income settings by describing the distribution of plasma IGF-
I concentrations at 6, 18, and 30 mo of age among a group
of children in Malawi and comparing the values to those of
a well-growing child population in a high-income country.
Furthermore, we aimed to develop a pathway map to illustrate
how undernutrition, viral, bacterial, and parasitic infections,
systemic and intestinal inflammation, and other maternal, child,
and environmental variables are associated with plasma IGF-I
concentration, and eventually child’s length or height gain, in the
Malawian setting.
Methods
Study design and concept map
This was a secondary analysis of data and biological samples
(plasma and stool) that were prospectively collected as part of
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a dietary intervention trial in Malawi [the International Lipid-
Based Nutrient Supplements Project DYAD–Malawi (iLiNS-
DYAD-M)] and from an observational birth cohort study in Fin-
land [Type 1 Diabetes Prediction and Prevention study (DIPP)].
From both cohorts, we analyzed the plasma IGF-I concentration
at 6, 18, and 24–36 mo of age in the participants to describe its
distribution in apparently healthy children representing different
average growth patterns. We then used 2 different statistical
approaches to identify direct and indirect predictors of plasma
IGF-I concentration at 18 mo—an age when other hormones such
as insulin or sex steroids play a minor role in driving child growth
(12). The pathway analysis was performed only in the Malawian
children, among whom growth restriction was common.
Study participants
From Malawi, we included children who had participated in
the iLiNS-DYAD-M dietary intervention trial and contributed
any anthropometric, laboratory, or environmental exposure data
to the analysis. The full details of this trial have been described
elsewhere (clinicaltrials.gov identifier NCT01239693) (13, 14).
In brief, iLiNS-DYAD-M was a randomized, outcome
assessor-blinded, 3-arm intervention trial that took place in rural
Malawi from February 2011 to April 2015. The primary aim of
the trial was to study the impact of small-quantity lipid-based
nutrient supplements (SQ-LNS) on maternal and child outcomes,
especially birth size and child’s growth.
Participants in the iLiNS-DYAD-M trial were pregnant women
who were enrolled before 20 weeks of gestation and their
offspring. In the first control group, women were provided with
iron and folic acid supplements during pregnancy. In the second
control group, women were provided with multiple micronutrient
supplements during pregnancy and the first 6 mo of lactation.
In the intervention group, women were provided with SQ-LNS
during pregnancy and the first 6 mo of lactation and children were
provided with SQ-LNS from 6 to 18 mo of age. The children
were followed-up until 30 mo of age, with regular anthropometric
assessment and biological sample collection at 6, 18, and 30 mo
of age. At the time of biological sample collection, all children
were apparently healthy—that is, their caretakers did not report
any illness symptoms for the children.
The Finnish sample was derived from the DIPP study
(clinicaltrials.gov identifier NCT03269084) – a population-based
long-term clinical follow-up study established since 1994 in
3 university hospitals in Finland. The aim of the Finnish DIPP
study is to understand the pathogenesis of type 1 diabetes,
predict the disease, and find preventive treatments. Recruitment is
based on screening of HLA-DR-DQ genotypes from cord blood
sample. Children who carry HLA genotypes associated with
increased risk to develop type 1 diabetes are invited to follow-up
and monitored for the development of islet autoimmunity. The
subjects of the current analysis participated in regular follow-up
visits from early infancy to 15 y of age or until type 1 diabetes
was diagnosed, with clinical examination and biological sample
collection at the ages of 3, 6, 9, 12, 18, and 24 mo and thereafter
once a year (15). The participants selected for this analysis were
from the clinical DIPP center at Tampere University Hospital,
Finland.
Ethical approval was obtained from the College of Medicine
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Committee of Pirkanmaa Hospital District. Only participants
whose caregivers gave an informed consent were enrolled in the
study.
Biological specimen collection and processing
Clinic nurses collected the nonfasting Malawian blood sam-
ples from the antecubital vein. A trained lab technician separated
plasma into storage vials. Stool samples were collected by
mothers from participating children in their homes. If a child
had diarrhea, no stool sample was collected, and the visit was
postponed by 2 wk. Plasma and stool samples were later shipped
to Tampere University in Finland and Washington University in
St. Louis, MO, on dry ice for analysis. For the current study, we
included data from all participants at the ages of 6, 18, and 30 mo
with any postnatal anthropometric measurements and any plasma
or stool samples.
In the DIPP study, study nurses collected blood samples from
the antecubital vein. Blood samples were taken using CPT tubes
(BD Biosciences), and plasma was separated according to the
manufacturer’s instructions into storage vials and stored at –80◦C
until analysis.
Analyses of plasma IGF-I concentration
Carrier-protein–free IGF-I concentration was analyzed from
stored plasma samples using the commercial MILLIPLEX®
MAP HIGF-I, II Magnetic Bead Panel Kit (catalog no.
HIGFMAG-52K; EMD Millipore), according to the manu-
facturer’s instructions. Properly diluted plasma samples were
incubated with the antibody-coupled microspheres and then
with biotinylated detection antibody before the addition of
streptavidin–phycoerythrin. The captured bead complexes were
measured with the Bio-Plex® 200 system (Bio-Rad Laborato-
ries). The detection range of the assay was 0.12–88.2 ng/mL.
Other laboratory analyses
Plasma C-reactive protein (CRP) and α1-acid glycoprotein
(AGP) were analyzed on a Roche Cobas 6000 analyzer (Roche
Diagnostics). Plasma cytokines—IL-1β, IL-6, IL-10, and TNF-
α—were measured using the commercial MILLIPLEX® MAP
kit (EMD Millipore). Malaria was diagnosed on-site from finger-
prick blood samples using the rapid diagnostic test Clearview
Malaria Combo (British Biocell International). Maternal HIV
infection at study enrollment was tested with a whole-blood
antibody rapid test (Alere Determine HIV-1/2; Alere Medical);
for children, no HIV tests were done.
Stool samples were assayed using commercially available
ELISA kits for calprotectin (Hycult Biotech). Campylobac-
ter (16), Shigella (17), Cryptosporidium spp., Giardia (18),
enterovirus, rhinovirus, parechovirus, norovirus, and rotavirus
infections were detected using an in-house real-time PCR assay
that has been shown to be specific and sensitive for detecting these
microbes, including the rhinovirus, from stool samples (19, 20).
Microbiota data were obtained from the stool samples using
previously described DNA extraction and high-throughput 16S
sequencing methods (21, 22). The microbiota-for-age z score
(MAZ) as a measure of microbiota maturity was obtained by
comparing the microbiota ages of participants to the median
microbiota age of same-aged children in the reference group gen-
erated with a random forests (RF)–derived model, as described
previously (21, 22).
Anthropometric assessment
Trained anthropometrists measured the mothers’ and chil-
dren’s weight and length/height in triplicate, as described
previously (13, 14). We calculated age- and sex-standardized
anthropometric indices—length-for-age z score (LAZ), weight-
for-age z score (WAZ), and weight-for-length z score (WLZ)—
using the WHO Child Growth Standards (23). No outlier data
points were removed from the data before analysis.
Morbidity and other data collection
Data collectors visited the children’s homes weekly to collect
child’s morbidity information, which was recorded using a
picture calendar by a caregiver. Morbidity variables included
fever, diarrhea, and respiratory symptoms recorded in the
previous 7 d. No antibiotic exposure data were collected.
Sociodemographic information was collected through per-
sonal interviews with mothers. A household assets score was
created using principal component analysis based on information
on building materials of the house, electricity, and cooking fuel.
Pathway analysis
We based our pathway analysis on a concept map (Supple-
mental Figure 1), according to which plasma IGF-I concentra-
tions would be directly predicted by the child’s current nutritional
status (WLZ) and systemic inflammation marker (AGP) (10,
11, 24). In addition, we hypothesized that maternal height and
nutritional status [BMI (in kg/m2)] would be associated with the
child’s plasma IGF-I concentration through a parental genetic
component shared with the child and nutrients or growth factors
given to the child through breast milk (25–28). Moreover, we
expected a seasonal effect on IGF-I expression as documented
in several animal species (29–31).
The presumed indirect predictors covered mothers’ education;
children’s fecal calprotectin concentration as a marker of
intestinal inflammation; malaria; bacterial (Campylobacter and
Shigella), parasitic (Giardia and Cryptosporidium), and viral
(enterovirus, rhinovirus, parechovirus, norovirus, and rotavirus)
infections; intestinal microbiota composition (MAZ); children’s
clinical morbidity (fever, cough, or diarrhea); and socioeconomic
and environmental exposures (household assets, water source,
and sanitation). Factors that could be part of the etiological
pathway but could not be identified as predictors with the
collected data are marked with a dashed line in Supplemental
Figure 1.
Statistical analysis
We compared proportions, means, and SDs between groups
by using Student’s t test for continuous variables and Fisher’s
exact test for proportions. For selected analyses, we summarized
systemic inflammation markers (CRP, AGP, IL-1β, IL-6, IL-10,
and TNF-α) into a single principal component and treated
the principal component score as a continuous variable. We
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component score variables into quintiles, and we tested the
dose–response of child’s plasma IGF-I concentration by quintiles
of the predictor using the extended Wilcoxon’s rank-sum test
(32).
The monthly change in z scores of LAZ and WLZ was
calculated using linear models to obtain an estimate. The
estimates were standardized for the relative monthly changes in
z scores, and seasonal fluctuation during the year was illustrated
by using locally weighted scatterplot smoothing.
We identified the predictors of plasma IGF-I concentration by
examining the relations between the dependent and independent
variables. For dichotomous predictor variables, we calculated
the mean plasma IGF-I concentration per group and tested
the difference between groups. For continuous predictors, we
assessed linear relations graphically with scatterplots and used
linear models to assess the strength of the associations.
In order to meet the assumption of normality in the models,
we assessed the normality of each variable and applied natural
logarithmic transformation in cases with extreme skewness. For
principal component scores, the variables were also centered and
scaled. Normalization procedures were not applied to child’s
plasma IGF-I concentration because central limit theorem dic-
tates that parametric analysis of means is valid and robust despite
the shape of the outcome variable’s distribution, if the sample
size is large (33). The continuous variables were standardized
in the generalized structural equation model (GSEM) for easier
interpretation of the associations.
We analyzed the causal relations between direct and indirect
predictors and plasma IGF-I concentration with the structural
equation model (SEM) and GSEM. GSEM was selected as
the method of choice for the final pathway model because
1) it allows for the usage of a variable as both endogenous
(outcome) and exogenous (predictor) in the same model and 2) as
opposed to SEM, GSEM allows for usage of generalized linear
models. This enabled the use of binary or count variables as
outcome variables in the modeling. Missing data were handled
by using the full-information maximum-likelihood method in the
SEM model and multiple imputation using chained equations
in the GSEM model. The set of variables included in the
pathway model was determined by a series of generalized linear
models.
We conducted sensitivity analysis using an RF machine
learning method, which utilized an ensemble of regression
models to predict the value of an outcome variable, child’s
plasma IGF-I concentration. With RF, we tested the robustness
of identified predictors in the pathway model by determining the
importance of the explanatory variables with the change in mean
squared error. Missing values for predictors were imputed into
the data using proximity from the RF model. The number of trees
used in the model was 1000, and number of variables available
for splitting nodes was set to 5.
All statistical analyses were done using either Stata version
15.1 (StataCorp) or R version 3.4.4 software (R Foundation for
Statistical Computing).
Results
Among 790 live-born Malawian infants, 697 (87.5%), 691
(86.7%), and 597 (74.9%) had available anthropometric data at
6, 18, and 30 mo, respectively (Supplemental Figure 2). Of
the 80 Finnish participants, we had 78, 79, 62, and 63 plasma
samples from children at 6, 18, 24, and 36 mo, respectively. At
6 mo of age, the mean ± SD LAZ, WAZ, and WLZ of Malawian
infants were –1.26 ± 1.14, –0.57 ± 1.18, and 0.36 ± 1.15, and
the corresponding z scores for Finnish infants were 0.77 ± 1.00,
0.72 ± 1.04, and 0.49 ± 1.15, respectively (Table 1). The
proportion of boys was slightly higher in the Finnish than
the Malawian sample (54.2% compared with 47.2%), but the
difference was not statistically significant (P = 0.29) (Table 1).
Malawian infants excluded from this study were on average
similar to the included ones, except that their mean household
asset score was higher and their mothers’ mean BMI was slightly
lower (Table 1). The proportion of mothers with a positive HIV
test was 11.9%.
In Finland, the mean ± SD plasma IGF-I concentrations were
13.4 ± 7.6, 24.2 ± 11.3, 26.9 ± 13, and 30.8 ± 12.9 ng/mL at
6, 18, 24, and 36 mo of age, respectively. In Malawi, they were
13.0 ± 8.2, 12.5 ± 7.7, and 14.6 ± 10.7 ng/mL at 6, 18, and 30 mo
of age, respectively. Accordingly, the mean IGF-I concentration
was similar in Finland and Malawi at 6 mo of age, whereas at age
18 mo and older, the mean concentration was higher in Finland
than in Malawi [age- and sex-adjusted difference (95% CI) at
18 mo: 11.8 (9.9, 13.7) ng/mL; P < 0.01] (Figure 1). In relative
terms, at 18 mo of age, the Finnish children had a 94% (95%
CI: 73, 114%) higher mean plasma IGF-I concentration than the
Malawian children.
There was a weak, albeit significant, association between
Malawian children’s LAZ and WLZ at 18 mo of age and their
concurrent plasma IGF-I concentration (r = 0.18, P < 0.001 and
r = 0.17, P < 0.001, respectively) (Figure 2).
Systemic inflammation was strongly associated with a lower
plasma IGF-I concentration, in a dose-dependent manner, with
children in the highest inflammation quintile having almost
50% lower mean IGF-I plasma concentration than children
in the lowest inflammation quintile (Table 2). In contrast,
there was no association between the children’s plasma IGF-I
concentration and their intestinal inflammation, as assessed by
stool calprotectin concentration (Table 2).
Children with intestinal Campylobacter or Shigella infection
or blood malaria parasitemia had a significantly lower mean
plasma IGF-I concentration compared with their uninfected
peers, whereas no similar association was evident for intestinal
Cryptosporidium or Giardia infection (Table 3). There was
also no association between plasma IGF-I concentration and the
detection of noro-, parecho-, or rhinovirus in the stool. Children
with intestinal enterovirus or rotavirus infection had a lower
mean plasma IGF-I concentration, but the difference was not
statistically significant (P = 0.051 for enterovirus and P = 0.52
for rotavirus) (Table 4). No linear relation was observed between
the plasma IGF-I concentration and MAZ or children’s clinical
morbidity (fever, cough, or diarrhea) within the past 7 d (data
not shown).
The plasma IGF-I concentration in Malawian children was
positively associated with maternal education and sanitation.
Other environmental exposures (water source and household
assets) and remaining maternal characteristics (height and BMI)
were not directly associated with the plasma IGF-I concentration
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TABLE 1 Baseline characteristics of the included and excluded Malawian and Finnish children1
Malawi
Characteristic Included Excluded P value Finland
Participants, n 716 80 80
Age, y 0.5 ± 0.08 — 0.5 ± 0.03
Proportion of boys, % 47.2 52.0 0.37 54.2
LAZ –1.26 ± 1.14 — 0.77 ± 1.0
WAZ –0.57 ± 1.18 — 0.72 ± 1.04
WLZ 0.36 ± 1.15 — 0.49 ± 1.15
Unsafe water source,2 % 9.0 6.7 0.67
Unsafe sanitary facilities,3 % 90.2 93.4 0.53
Household asset z score –0.05 ± 0.97 0.43 ± 1.16 <0.001
Maternal age at enrollment, y 25 ± 6 24 ± 7 0.61
Maternal height, cm 156.3 ± 5.7 155.7 ± 5.4 0.68
Maternal BMI, kg/m2 21.6 ± 2.8 22.9 ± 3.1 0.04
Mother’s education, y 3.9 ± 3.5 4.0 ± 3.5 0.76
1Values are means ± SDs or percentages unless otherwise indicated. Student’s t test for continuous variables and
Fisher’s exact test for proportions. LAZ, length-for-age z score; WAZ, weight-for-age z score; WLZ, weight-for-length
z score.
2Unprotected well, lake, or pond.
3Regular pit latrine or no latrine.
Figure 3 shows the variation in mean plasma IGF-I concentra-
tion and the standardized change in LAZ and WLZ by calendar
month among 18-mo-old Malawian children. All seasonal curves
followed a similar pattern, but with slightly different schedules.
The mean average monthly change in WLZ peaked in May and
June, whereas both the plasma IGF-I concentration and the mean
average monthly change in LAZ peaked 1–2 mo later, in June–
August (Figure 3).
Figure 4 shows results from the GSEM analysis, as a
visualization of the direct and indirect predictors of plasma
IGF-I concentration among 18-mo-old Malawian children.
IGF-I concentration was inversely associated with systemic
FIGURE 1 The distribution of plasma IGF-I concentration among Finnish and Malawian infants and children aged 6–36 mo (FI: n = 78, 79, 62, and 63
at 6, 18, 24, and 36 mo, respectively; MW: n = 520, 606, and 580 at 6, 18, and 30 mo, respectively). At age 18 mo, the age- and sex-adjusted difference in the
mean plasma IGF-I concentration between Finnish and Malawian children was 11.8 ng/mL (95% CI: 9.9, 13.7 ng/mL; P < 0.01). Student’s t test was used to
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FIGURE 2 The association between plasma IGF-I concentration and length-for-age and weight-for-length z scores at age 18 mo among Malawian children
(n = 604). Correlation analysis was used to quantify the relation between each pair of variables. IGF-I, insulin-like growth factor I.
inflammation and intestinal enterovirus infection and positively
associated with the children’s WLZ, female sex, maternal
height, and dry season. Other variables in the pathway map
were associated with the plasma IGF-I concentration indirectly
(Figure 4). The indicated model had a good fit (root mean square
error of approximation = 0.038, Tucker–Lewis index = 0.82,
and comparative fit index = 0.91), and it explained 44% of the
variance in plasma IGF-I concentration.
The importance of systemic inflammation, WLZ, and child’s
sex as predictors of the children’s plasma IGF-I concentration
was confirmed in an RF model (Supplemental Figure 3).
Systemic inflammation was the most important variable in
predicting plasma IGF-I concentration (improving the accuracy
by 18.4%), followed by child sex (10.7%), WLZ (6.3%), malaria
infection (4.1%), MAZ (2.3%), and enterovirus infection (1.3%)
(Supplemental Figure 3).
Discussion
We aimed to characterize biological pathways associated with
plasma IGF-I concentration in children in a low-income setting
by describing their plasma IGF-I concentration and identifying
direct and indirect predictors of the IGF-I concentration. The
mean plasma IGF-I concentrations were similar in the 2 countries
in children aged 6 mo. Thereafter, plasma IGF-I concentrations
increased among the Finnish but not the Malawian children, so
that at age 18 mo, the mean value in Malawi was only half of
that in Finland. Among the Malawians, plasma IGF-I concen-
tration was inversely associated with systemic inflammation and
intestinal enterovirus infection and positively associated with the
children’s WLZ, female sex, maternal height, and dry season.
Malaria parasitemia, intestinal Shigella and Campylobacter
infection, and intestinal inflammation were positively associated
with systemic inflammation and hence indirectly also with
plasma IGF-I concentration, whereas there was no similar
association for intestinal Giardia, Cryptosporidium, or other viral
infections. Seasonally, mean plasma IGF-I concentrations peaked
in June and July and showed a nadir in December and January,
coinciding with changes in children’s length gain and preceded
by ∼2 mo by the changes in their WLZ.
Internal validity could have been compromised by errors
or differences in laboratory processes, missing data, or the
choice of modeling techniques. External validity could have been
affected by the choice of variables in the analyses. However,
we used similar and standardized biological sample collection,
processing, and storage procedures in Malawi and Finland and
performed all laboratory assays according to the manufacturer’s
instructions. Furthermore, the excluded participants and those
TABLE 2 The association between systemic or intestinal inflammation and plasma IGF-I concentration among Malawian children at 18 mo of age1
Mean plasma IGF-I concentration among children with various levels of inflammation,
ng/mL
Marker of inflammation 1st quintile2 2nd quintile 3rd quintile 4th quintile 5th quintile P value3
Plasma AGP concentration 15.2 13.0 11.9 9.1 7.3 <0.001
Plasma CRP concentration 14.9 14.0 12.9 11.4 8.9 <0.001
Principal component score for systemic inflammation 15.2 13.4 12.0 10.9 8.9 <0.001
Fecal calprotectin concentration 12.8 12.7 12.3 12.6 11.5 0.66
1AGP, α1-acid glycoprotein; CRP, C-reactive protein; IGF-I, insulin-like growth factor I.
2Children in the lowest quintile of the inflammation marker (lowest 20%).
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TABLE 3 The association between selected bacterial and parasitic infections, malaria, and plasma IGF-I concentration among Malawian children at 18 mo
of age1
Plasma IGF-I concentration,2 ng/mL
Detected infection (no. of children
with negative/positive test result)
Children with negative
test result for infection
Children with positive
test result for infection
Difference
(95% CI) P value3
Intestinal Campylobacter (186/405) 13.6 ± 6.7 11.8 ± 9.2 –1.8 (–3.3, –0.3) 0.0214
Intestinal Shigella (538/51) 12.7 ± 7.7 9.4 ± 5.7 –3.3 (–5.0, –1.6) <0.001
Intestinal parasite
Intestinal Cryptosporidium (573/15) 12.5 ± 7.5 12.4 ± 13.6 –0.04 (–4.0, 3.9) 0.225
Intestinal Giardia (270/318) 12.8 ± 7.8 12.1 ± 7.6 –0.7 (–2.0, 0.6) 0.27
Blood parasite
Blood malaria parasitemia (524/61) 12.8 ± 7.7 9.9 ± 7.4 –2.9 (–4.9, –0.8) 0.01
1IGF-I, insulin-like growth factor I.
2Means ± SDs.
3P values obtained using Student’s t test.
4Degrees of freedom for the t test obtained from Welch’s formula due to unequal variances.
5Wilcoxon–Mann–Whitney sum of ranks test.
with missing data had on average similar baseline characteristics
compared with participants who provided data, and we used
multiple imputations to model the missing values (34). Finally,
we included variables that had been considered appropriate in
previous analyses (10, 11, 24, 35), and the results were robust to
sensitivity analyses with RF modeling. Therefore, we believe that
the sample findings are valid and representative of the population
from which they were drawn.
According to earlier literature, mean plasma IGF-I concen-
trations in normally well-growing children are lowest at 6–
8 mo of age, rise relatively steadily until puberty, and then
fall to lower adult concentrations (36–39). Our findings in the
Finnish sample are thus similar to those observed in Sweden (36),
Turkey (37), Denmark (38), and Germany (39). Similarly, our
findings from Malawi match those from a study in Zimbabwe,
documenting low mean plasma IGF-I concentrations at 6 and
18 mo of age (40). These results suggest that the age-dependent
rise in plasma IGF-I concentration is prevented or delayed in
some low-income settings, leading to growth faltering in late
infancy and early childhood. This would fit well with the infancy–
childhood–puberty model of growth, according to which the
mostly nutrition-dependent early infancy growth is gradually
replaced by growth-hormone– and IGF-I–dependent childhood
growth, which is eventually superimposed by a sex-steroid–
driven growth spurt during puberty (41). The growth hormone–
dependent growth is strengthened between 6 and 12 mo of age,
and a delay in this phase has been suggested to explain at least
part of the linear growth faltering seen in low-income settings
(42, 43).
The fact that Malawian infants were on average markedly
shorter than the Finnish infants at 6 mo of age, despite a similar
mean plasma IGF-I concentration, can partially be explained
by a high proportion of preterm births. Because of a shorter
fetal period, newborns in the iLiNS-DYAD-M trial had less time
to grow and they were shorter and lighter than children in an
international reference already at birth (14). In addition, during
the fetal period and early infancy, linear growth is promoted by
other hormones that we did not study, such as IGF-II, insulin, and
thyroid hormones (8). Thus, there may have been a difference in
the hormonal drivers of growth before 6 mo of age.
The list of predictors of children’s plasma IGF-I that
we identified is mostly consistent with previous literature.
Weight-for-length/height stimulates growth-hormone and IGF-
I production in children (12); cough, fever, and diarrhea are
inversely associated with plasma IGF-I concentration; and
inflammatory cytokines interfere with IGF-I expression in liver
TABLE 4 The association between selected viral infections and plasma IGF-I concentration among Malawian children at 18 mo of age1
Plasma IGF-I concentration,2 ng/mL
Detected infection (no. of children
with negative/positive test results)
Children with negative
test result for infection
Children with positive
test result for infection
Difference
(95% CI) P value3
Enterovirus (88/500) 14.2 ± 9.0 12.2 ± 7.4 –2.0 (–4.0, 0.01) 0.0514
Rhinovirus (560/28) 12.4 ± 7.7 13.7 ± 7.6 1.3 (–1.7, 4.2) 0.40
Parechovirus (498/90) 12.5 ± 17.4 12.0 ± 9.1 –0.6 (–2.3, 1.2) 0.51
Norovirus (541/47) 12.5 ± 7.8 11.9 ± 7.0 –0.6 (–2.9, 1.7) 0.63
Rotavirus (584/4) 12.5 ± 8.7 10.4 ± 7.7 –2.1 (–9.7, 5.5) 0.525
1IGF-I, insulin-like growth factor I.
2Means ± SDs.
3P values obtained using Student’s t test.
4Degrees of freedom for the t test obtained from Welch’s formula due to unequal variances.
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FIGURE 3 Seasonal variation among Malawian children in plasma IGF-I concentration and standardized monthly change in their WLZ and LAZ at age 18
mo (n = 605). The monthly change in WLZ and LAZ was calculated using linear models to obtain an estimate. The estimates were standardized for the relative
monthly changes in z scores, and seasonal fluctuation during the year was illustrated by using locally weighted scatterplot smoothing. IGF-I, insulin-like growth
factor I; LAZ, length-for-age z score; WLZ, weight-for-length z score.
cells (10–12, 44). Girls have been repeatedly shown to have
higher mean IGF-I concentration compared with boys, likely
because of their genetic constitution (36, 37, 39), and the same
probably applies to children of taller mothers. We could not
find earlier human studies on the seasonality of plasma IGF-I
concentration, but vitamin D has been found to increase IGF-
I concentration in adults (45), and the seasonality phenomenon
has been documented and associated with light exposure
in many animal species (29–31). Additional exposures that
were not included in our models but are likely to explain
part of the remaining variability in children’s plasma IGF-I
concentration include their genetic constitution, liver function,
activity of other growth-related hormones, nutritional exposures
not reflected in concurrent WLZ, and children’s HIV status
(25–27).
One striking finding in our analysis was the consistent
associations between microbial detection in blood or stools
and reduced IGF-I concentration among children who did not
have apparent disease symptoms at the time of the biospecimen
collection. The impact of acute illness on linear growth is well
documented (46–49), and this impact has often been attributed
to anorexia, reduced nutrient intake, nutrient loss, increased
catabolism, and nutrient sequestration (50, 51). A study in rural
Zimbabwe suggested that children with acute infections have
reduced plasma IGF-I concentration (11), and similar results have
been reported in relation to many other symptomatic infections,
such as bacterial sepsis (52), leprosy (53), and hepatitis C (54).
Thus, infection- and inflammation-related IGF-I downregulation
seems to be another important mechanism that links infection,
disease, and growth restriction in low-income settings. Our
results and those of others suggest that such downregulation
also takes place during many clinically nonapparent infections
(44, 55). The direct association between enteroviral carriage
and lower plasma IGF-I concentration could be a spurious
finding. However, it might also be a true causal association
because enteroviral infection has been associated with a marked
downregulation of IGF-II expression in a cell-culture condition
(56).
We could not find any other study that examined concurrent
seasonal patterns in plasma IGF-I concentration, change in
length for age, and change in weight for length among children.
However, several previous studies have described a seasonal
pattern of ponderal and linear growth in low-income settings,
with peak annual weight gains typically following harvest
season and preceding peak height gains by some months (57,
58). Similarly, in the recovery from severe acute malnutrition,
children typically first gain weight before they start gaining
length/height (59). These findings and ours are compatible with
a theory that increased food security and intake promotes fat
deposition in growing children, resulting in leptin synthesis and
somewhat later enhanced growth hormone and IGF-I secretion
and increased length or height gain. Additional seasonal effects
could be mediated by variation in infection prevalence and
inflammation, and possibly light exposure.
Two limitations of our study are the small sample size and
limited data availability for the Finnish cohort and lack of
direct evidence between plasma IGF-I concentration of children’s
linear growth in the Malawian sample. Therefore, we could not
complete full pathway analyses for both cohorts. The sample
sizes were, however, sufficient to demonstrate marked differences
in the mean IGF-I concentration between the populations. And
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FIGURE 4 Pathway model for the determinants of plasma IGF-I concentration among Malawian children aged 18 mo. Red lines indicate negative
associations, and blue lines indicate positive associations. The hypothesized causal relations between direct and indirect predictors and plasma IGF-I
concentration were analyzed with SEM and GSEM. AGP, α1-acid glycoprotein; GSEM, generalized structural equation modeling; IGF-I, insulin-like growth
factor I; SEM, structural equation modeling.
18-mo-old children (8), the variance in its concentration is
likely to explain a significant proportion of the observed growth
difference between the 2 populations. Furthermore, plasma IGF-I
concentration that swiftly responds to external stimuli is likely a
better outcome variable than linear growth for studies identifying
factors that restrict child growth. This is because many of the
exposures (e.g., infection) are temporary and hence exposure
status at 1 point is not predictive for the subsequent 3–6 mo,
which is typically the shortest interval for length measurement.
In summary, we have shown that IGF-I concentrations are
considerably lower among 18- to 36-mo-old children in Malawi
than in Finland, that seasonal variation in children’s growth
parallels very closely that of plasma IGF-I concentration, and
that systemic inflammation and clinically nonapparent infections
are common and strongly associated with reduced plasma IGF-
I concentrations in Malawi. Based on these findings and the
literature that we reviewed, we argue that broad and effective
infection prevention and management programs are essential for
successful promotion of healthy child growth in low-income
settings.
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